GU Cancers 2022 | The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, provides an overview of the results of the Phase III PROpel (NCT03732820) study exploring the value of early use of the PARP inhibitor (PAPRi) olaparib in combination with abiraterone for metastatic castration resistant prostate cancer (mCRPC). Dr Armstrong explains the unique aspect of this study is investigating the PARPi in unslected patients, as Olaparib is traditionally used to treat men with BRCA2 mutations, as well as other DNA repair defects. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.